New eyedrop aims to halt progressive eye disease
Disease control
ENROLLING_BY_INVITATION
This early-stage trial tests TN-001 eyedrops in 20 adults with progressive keratoconus, a condition that thins and bulges the cornea. Participants use the drops twice daily for 3-6 weeks. The main goals are to check safety and see if the drops can stop the disease from advancing.
Phase: PHASE1, PHASE2 • Sponsor: TheiaNova Ltd. • Aim: Disease control
Last updated May 17, 2026 05:04 UTC